Sign in

CIK 0001841387 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Candel Therapeutics, Inc.

Sign in to watch
Ticker
CADL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
522214851
Phone
617-916-5445
Business address
117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$3,244,783
in 2 filings, $3.2M under 10b5-1 plans

Net −$3,244,783. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Tak Paul Peter −$3.2M Chief Executive Officer sold 71% of stake
  2. Tyagarajan Seshu −$84K Chief Technology Officer sold 8% of stake
Date Insider Transaction Shares Price Value Owned after
2021-07-29 Manning Paul B Director Conversion +553,752 553,752
2021-07-29 Manning Paul B Director Conversion · Series B Preferred Stock −1,669,303 0
2021-07-29 Manning Paul B Director Conversion · Series B Preferred Stock −1,361,069 0
2021-07-29 Canepa John J Chief Financial Officer Purchase +10,125 $8.00 $81K 10,125
2021-07-29 Aguilar Laura K. Chief Medical Officer Conversion +56,096 931,039
2021-07-29 Aguilar Laura K. Chief Medical Officer Conversion · Series B Preferred Stock −137,881 0
2021-07-29 Caffo Nathan Chief Business Officer Purchase +6,000 $8.00 $48K 6,000
2021-07-29 Manning Paul B Director Purchase +20,000 $7.30 $146K 56,000
2021-07-27 Manning Paul B Director Purchase +36,000 $7.36 $265K 36,000

Page 13 of 13 · 249 trades